Bicara Therapeutics Inc. (BCAX)
NASDAQ · Healthcare
$27.15-2.20%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.52B
- P/E ratio
- —
- EPS
- —
- Volume
- 281,485
- 52-week high
- —
- 52-week low
- —
- Open
- $27.77
- Day high
- $28.07
- Day low
- $27.10
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$137.95M | -$2.52 |
| 2024 | — | -$68M | -$4.05 |
| 2023 | — | -$51.99M | -$89.61 |
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
- CEO
- Claire Mazumdar Clemon
- Employees
- 103
- Country
- US
- IPO date
- Sep 13, 2024
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Bicara Therapeutics Inc.'s stock price today?
- BCAX is trading at $27.15 as of Jul 20, 2026.
- What is Bicara Therapeutics Inc.'s market cap?
- Bicara Therapeutics Inc. (BCAX) has a market capitalization of $1.52B.
- Does Bicara Therapeutics Inc. pay a dividend?
- Bicara Therapeutics Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Bicara Therapeutics Inc. in?
- Bicara Therapeutics Inc. operates in the Healthcare sector.